Stereotaxis (STXS)
:STXS
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated substantial strategic and regulatory progress — including U.S./EU approvals for GenesisX, MAGiC and MAGiC Sweep, double-digit revenue growth and clear commercial and manufacturing ramp plans — while also acknowledging meaningful operational challenges: catheter manufacturing constraints, a sharp quarter-on-quarter recurring revenue decline, increased negative free cash flow and persistently low system gross margins. Management provided concrete remediation plans (manufacturing scale-up, Osypka ramp to ~500 catheters/month, Synchrony commercialization, and mixed capital/placement sales models) and positive 2026 guidance (> $40M revenue), signaling a constructive outlook if execution continues. Overall, the highlights (regulatory wins, revenue growth, margin improvement potential and clear go-to-market plans) outweigh the operational lowlights, but execution risk remains material.Company Guidance
Regulatory Approvals for Core Products
Achieved U.S. and European regulatory approvals for GenesisX robot, MAGiC Ablation Catheter and MAGiC Sweep mapping catheter — milestone regulatory wins establishing a foundation for EP commercialization and multi-product adoption.
Revenue Growth
Full-year 2025 revenue of $32.4M, up ~20.5% from $26.9M in 2024; Q4 2025 revenue $8.6M, up 36% year-over-year from $6.3M.
System Revenue Acceleration
Full-year system revenue of $10.2M versus $8.6M prior year (≈18.6% increase); Q4 system revenue surged to $3.3M from $1.4M in prior year quarter (≈+135.7%), driven by partial recognition on Genesis systems and ancillary device sales.
Recurring Revenue Expansion
Full-year recurring revenue grew to $22.2M from $18.3M in prior year (≈+21.3%), reflecting increased catheter revenue and early commercial traction for MAGiC products.
Strong Gross Margins and Future Margin Upside
Reported gross margin ~50% in Q4 and ~53% for full year 2025; full-year recurring gross margin of 67% and system gross margin of 21%, with guidance expecting recurring margins >75% and system margins >50% within ~3 years as volumes scale.
Improved Adjusted Operating Performance
Adjusted operating expenses for full-year 2025 were $26.3M vs $27.0M prior year; adjusted operating loss improved to $9.3M (2025) from $12.4M (2024), and adjusted quarterly operating loss improved to $2.6M from $3.8M year-over-year.
Commercial and Manufacturing Ramp Plans
Manufacturing plan to produce ~1 GenesisX every 2 months at current facility with ability to scale to several dozen/year; Osypka production plan targets ~500 MAGiC catheters/month by year-end after expected >100 catheters delivered in March.
Synchrony Digital Suite Momentum
Received CE Mark for Synchrony; FDA interaction complete with expected U.S. clearance in coming weeks and initial U.S. demand forecasted to generate over $3M in 2026 revenue; roadmap includes SynX connectivity and AI-enabled SaaS features.
Positive 2026 Guidance
Company expects double-digit revenue growth in 2026, quarterly revenue < $10M in H1 then > $10M in H2, and annual revenue to surpass $40M; expects reduced cash use in 2026 compared with 2025 and a working capital benefit.
Balance Sheet and Financing
Cash and cash equivalents of $13.4M at 12/31/25, no debt; raised $4.0M from registered direct financing and $3.1M from ATM during Q4 to support operations and ramp.
STXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 09, 2026 | $2.07 | $1.97 | -4.83% |
Nov 11, 2025 | $2.85 | $2.43 | -14.74% |
Aug 07, 2025 | $2.19 | $2.50 | +14.16% |
May 12, 2025 | $2.07 | $2.11 | +1.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Stereotaxis (STXS) report earnings?
Stereotaxis (STXS) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Stereotaxis (STXS) earnings time?
Stereotaxis (STXS) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STXS EPS forecast?
STXS EPS forecast for the fiscal quarter 2026 (Q1) is -0.05.